These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

79 related articles for article (PubMed ID: 3105046)

  • 41. The effect of aminoglycoside-induced adaptive resistance on the antibacterial activity of other antibiotics against Pseudomonas aeruginosa in vitro.
    Barclay ML; Begg EJ; Chambers ST; Peddie BA
    J Antimicrob Chemother; 1996 Nov; 38(5):853-8. PubMed ID: 8961055
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Study of in vitro selected resistance of Pseudomonas aeruginosa to cefoperazone, ceftazidime, azthreonam and imipenem.
    Van der Auwera P; Husson M; Bulliard G
    Drugs Exp Clin Res; 1986; 12(11):871-83. PubMed ID: 3102194
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Use of cefotaxime or ceftazidime susceptibility tests for predicting susceptibility of Enterobacteriaceae and Pseudomonas aeruginosa.
    Heym B; Lacroix O; Péan Y; Gertner J; Nicolas MH; Jarlier V
    J Antimicrob Chemother; 1994 Apr; 33(4):729-35. PubMed ID: 8056691
    [TBL] [Abstract][Full Text] [Related]  

  • 44. [Comparison of the in vitro activity of ceftazidime: in culture, in serum and in combination with granulocytes].
    Daschner FD; Bassler M; Grundau D; Dieterle L; Just HM
    Immun Infekt; 1983 Nov; 11(6):221-8. PubMed ID: 6439624
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Study quantifies impact of resistant Pseudomonas on outcomes.
    Kepple SR
    Am J Health Syst Pharm; 1999 Jul; 56(14):1392. PubMed ID: 10428444
    [No Abstract]   [Full Text] [Related]  

  • 46. Activity of ceftazidime/avibactam against problem Enterobacteriaceae and Pseudomonas aeruginosa in the UK, 2015-16.
    Livermore DM; Meunier D; Hopkins KL; Doumith M; Hill R; Pike R; Staves P; Woodford N
    J Antimicrob Chemother; 2018 Mar; 73(3):648-657. PubMed ID: 29228202
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Activities of piperacillin, ceftazidime, cefepime and cefpirome against Pseudomonas aeruginosa strains with intrinsic ticarcillin resistance.
    Bert F; Setbon PG; Lambert-Zechovsky N; Branger C
    Chemotherapy; 1996; 42(6):426-31. PubMed ID: 8957576
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Antibiotic resistance in Pseudomonas aeruginosa: an Italian survey.
    Bonfiglio G; Carciotto V; Russo G; Stefani S; Schito GC; Debbia E; Nicoletti G
    J Antimicrob Chemother; 1998 Feb; 41(2):307-10. PubMed ID: 9533479
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Development of resistance in wild-type and hypermutable Pseudomonas aeruginosa strains exposed to clinical pharmacokinetic profiles of meropenem and ceftazidime simulated in vitro.
    Henrichfreise B; Wiegand I; Luhmer-Becker I; Wiedemann B
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3642-9. PubMed ID: 17682103
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Activity of Ceftolozane-Tazobactam and Ceftazidime-Avibactam against Beta-Lactam-Resistant Pseudomonas aeruginosa Isolates.
    Humphries RM; Hindler JA; Wong-Beringer A; Miller SA
    Antimicrob Agents Chemother; 2017 Dec; 61(12):. PubMed ID: 28993338
    [TBL] [Abstract][Full Text] [Related]  

  • 51. The patterns and transmissibility of antibiotic resistance among clinical strains of Pseudomonas aeruginosa.
    Palillo ES; Salleh MA
    Microbiol Immunol; 1992; 36(11):1195-200. PubMed ID: 1491621
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo selection of oxacillinase-mediated ceftazidime resistance in Pseudomonas aeruginosa.
    Leotard S; Poirel L; Leblanc PE; Nordmann P
    Microb Drug Resist; 2001; 7(3):273-5. PubMed ID: 11759089
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bactericidal activity of ceftazidime against Pseudomonas aeruginosa under conditions simulating serum pharmacokinetic.
    Shah PM
    J Antimicrob Chemother; 1981 Sep; 8 Suppl B():135-40. PubMed ID: 19802977
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Quantitative variations in beta-lactam antibiotic released endotoxin from Pseudomonas aeruginosa: in-vivo relevance.
    Jackson JJ; Kropp H
    Prog Clin Biol Res; 1995; 392():235-51. PubMed ID: 8524928
    [No Abstract]   [Full Text] [Related]  

  • 55. Piperacillin and ceftazidime produce the strongest synergistic phage-antibiotic effect in Pseudomonas aeruginosa.
    Uchiyama J; Shigehisa R; Nasukawa T; Mizukami K; Takemura-Uchiyama I; Ujihara T; Murakami H; Imanishi I; Nishifuji K; Sakaguchi M; Matsuzaki S
    Arch Virol; 2018 Jul; 163(7):1941-1948. PubMed ID: 29550930
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Ceftazidime treatment in cystic fibrosis: resistant organisms in sputum and faeces.
    Dalzell AM; Sunderland D; Hart CA; Heaf DP
    Thorax; 1991 Apr; 46(4):239-41. PubMed ID: 1903896
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Dependence of the interaction of ceftazidime and gentamicin against Pseudomonas aeruginosa on the bacterial growth-rate.
    Chen HY; Jackson GG; Livermore DM
    J Antimicrob Chemother; 1991 Oct; 28(4):610-2. PubMed ID: 1761457
    [No Abstract]   [Full Text] [Related]  

  • 58. Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistant Pseudomonas aeruginosa in Riyadh, Saudi Arabia.
    Al-Agamy MH; Shibl AM; Tawfik AF; Elkhizzi NA; Livermore DM
    J Chemother; 2012 Apr; 24(2):97-100. PubMed ID: 22546765
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Further studies of transferable antibiotic resistance in strains of Pseudomonas aeruginosa from four clinical settings in three countries.
    Blahová J; Hupková-Lesická M; Králiková K; Krcméry V; Kubonová K; Torsová V; Bartoníková N; Schäfer V
    J Chemother; 1998 Jun; 10(3):215-20. PubMed ID: 9669646
    [TBL] [Abstract][Full Text] [Related]  

  • 60. In Vitro Activity of Ceftazidime-Avibactam against Contemporary Pseudomonas aeruginosa Isolates from U.S. Medical Centers by Census Region, 2014.
    Huband MD; Castanheira M; Flamm RK; Farrell DJ; Jones RN; Sader HS
    Antimicrob Agents Chemother; 2016 Apr; 60(4):2537-41. PubMed ID: 26810650
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.